Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GC4711 in Healthy Volunteers
NCT03762031Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rucosopasem manganese in pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by Galera Therapeutics, Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities. Started Mar 2019; status: completed.
02
Drugs
rucosopasem manganese
03
Conditions
pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03762031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762031.